Arcturus reports interim Phase 2 data for ARCT-810 in OTC deficiency trial
Bitget2026/09/23 20:01- Arcturus reported interim Phase 2 results for ARCT-810 in ornithine transcarbamylase deficiency, describing the drug as generally safe and well tolerated.
- Participants showed improvement in key disease markers, with effects sustained during periods of higher protein intake.
- The group introduced LUNAR 2.0, a next-generation mRNA delivery platform positioned to support lower or less frequent dosing in future programs.
- Dosing of next-generation candidate ARCT-2601 is planned near year-end in patients aged 12 and older within an amended Phase 2 protocol.
- Management plans to present additional details later today in an investor webcast.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
